U.S. Approved Biosimilars

Biosimilar Product (Manufacturer)Nonproprietary NameReference ProductDate Approved /
Date Marketed
Zarxio (Sandoz)filgrastim-sndzNeupogen (Amgen)March 2015 /
September 2015
Inflectra (Celltrion/Pfizer)infliximab-dyybRemicade (Janssen Biotech, Inc.)April 2016 /
November 2016
Erelzi (Sandoz)etanercept-szzsEnbrel (Amgen)August 2016
Amjevita (Amgen)adalimumab-attoHumira (AbbVie)September 2016
Renflexis (Samsung Bioepis Co., Ltd)infliximab-abdaRemicade (Janssen Biotech, Inc.)April 2017 /
July 2017
Cyltezo (Boehringer Ingelheim)adalimumab-adbmHumira (AbbVie)August 2017
Mvasi (Amgen)bevacizumab-awwbAvastin (Genentech)September 2017
Ogivri (Mylan/Biocon)trastuzumab-dkstHerceptin (Genentech)December 2017
Ixifi (Pfizer)infliximab-qbtxRemicade (Janssen Biotech, Inc.)December 2017
Retacrit (Hospira Inc.)epoetin alfa-epbxEpogen (Amgen Inc.)
Procrit (Janssen Products, LP)
May 2018 /
November 2018
Fulphila (Mylan/Biocon)pegfilgrastim-jmdbNeulasta (Amgen Inc.)June 2018 /
July 2018
Nivestym (Pfizer)filgrastim-aafiNeupogen (Amgen)July 2018 /
October 2018
Hyrimoz (Sandoz)adalimumab-adazHumira (AbbVie)October 2018
Truxima (Celltrion)rituximab-abbsRituxan (Biogen/Genentech)November 2018

None of the available biosimilars were approved as interchangeable.

Updated November 28, 2018